Health Care

Sanders sees moment may be right for drug importation bill

Bernie Sanders
Sen. Bernie Sanders, I-Vt., speaks at a news conference Tuesday about a drug importation bill. Photo by Jasper Craven/VTDigger
WASHINGTON — U.S. Sen. Bernie Sanders, I-Vt., introduced legislation Tuesday to battle escalating prescription drug prices by allowing for the importation of cheaper medicines from Canada, as long as they meet Food and Drug Administration standards.

Sanders has been pushing for drug importation for years, but his renewed effort comes as some Republicans, including President Donald Trump, have signaled an openness to taking on the pharmaceutical industry.

This bipartisan focus has been spurred, in part, by the recent skyrocketing prices of a number of lifesaving drugs. The price hike of the EpiPen, which has more than quintupled in cost since 2004, has sparked the most outrage. Evzio, an anti-opioid overdose drug injector, has increased more than sixfold in price over the last two years, leading U.S. Sen. Patrick Leahy, D-Vt., and other Democrats to demand answers from its maker in February.

American drug prices are among the highest in the world, largely because most other governments negotiate drug prices down. A 2015 study from the U.S. Centers for Disease Control and Prevention found that nearly 1 in 10 Americans can’t afford their prescription drugs.

“Millions of our people are getting sicker because they don’t have the medicine that they need,” Sanders said in a news conference Tuesday. “Some end up in emergency rooms at great cost, and others, frankly, lose their lives.”

“The goal of the pharmaceutical industry is to make as much profit as they can and to hell with the needs of the American people,” he added.

The Sanders bill would direct Health and Human Services Secretary Tom Price to develop regulations allowing pharmacies, wholesalers and individuals to gain access to Canadian drugs produced in accordance with FDA guidelines. All imported medicines would be required to have the same active ingredients and strength as current products in American pharmacies.

After two years of Canadian importation, additional countries that meet U.S. prescription standards would become eligible for importation.

The health secretary would be able to suspend importation if violations are discovered, such as the selling of counterfeit drugs. The bill creates strict penalties for those caught selling adulterated medicines, including up to 10 years in jail.

The Senate bill, called the Affordable and Safe Prescription Drug Importation Act, has attracted more than a dozen Democratic boosters, and companion legislation was introduced in the House by Reps. Elijah Cummings, D-Md., and Lloyd Doggett, D-Texas.

Though no Republicans have come on as co-sponsors, 12 Republicans voted for a largely symbolic budget amendment from Sanders earlier this session that would have allowed for drug importation. Sanders said Tuesday he hoped to announce Republican supporters soon, and he named Sen. John McCain, R-Ariz., as a potential ally of the bill.

Sanders said that although he was hopeful the bill would pass, the political power of pharmaceutical companies is unrivaled.

“These are people who never lose,” Sanders said. “These are people today who have 1,400 well-paid lobbyists right here, in the nation’s capital, including many former members, Democrats and Republicans from Congress. They have spent hundreds of millions of dollars in campaign contributions.”

It appears the industry has already moderated Trump’s position on lowering drug prices. After a meeting with pharmaceutical executives in late January, Trump appeared to abandon his promise to use the bargaining power of Medicare to lower costs.

“I’ll oppose anything that makes it harder for smaller, younger companies to take the risk of bringing their product to a vibrantly competitive market,” Trump said after a closed-door meeting with the executives. “That includes price-fixing by the biggest dog in the market, Medicare, which is what’s happening.”

Cummings is scheduled to meet next week with Trump to discuss, among other things, the importation drug bill. In the news conference Tuesday, one of the bill’s co-sponsors, Sen. Cory Booker, D-N.J., urged Trump to translate his rhetoric into action.

“It’s time for him to put up or shut up,” Booker said. “This bill is one of the things that can provide Americans cheaper access to drugs. It is time for him to join with us or confess his lies to the American people.”

If you read us, please support us.

Comment Policy requires that all commenters identify themselves by their authentic first and last names. Initials, pseudonyms or screen names are not permissible.

No personal harrassment, abuse, or hate speech is permitted. Comments should be 1000 characters or fewer.

We moderate every comment. Please go to our FAQ for the full policy.

Jasper Craven

About Jasper

Jasper Craven is VTDigger’s political reporter. A Vermont native, he first discovered his love for journalism at the Caledonian Record. He double-majored in print journalism and political science at Boston University, and worked in the Boston Globe’s Metro and Investigative units. While at the Globe he collaborated on Shadow Campus, a three-part investigative series focused on greed and mismanagement in Boston’s off-campus student housing market. The series was a finalist for the 2015 Pulitzer Prize.
He also spent two years at MuckRock, a news sited dedicated to investigation and analysis of government documents. 

Craven covered Vermont’s U.S. Congressional delegation for the Times Argus in the summer of 2014, and worked as a Metro reporter for the Chicago Tribune before joining the staff of VTDigger.

Email: [email protected]

Follow Jasper on Twitter @Jasper_Craven

Latest stories by Jasper

Recent Stories

Thanks for reporting an error with the story, "Sanders sees moment may be right for drug importation bill"
  • Steve Baker

    Bernie should work collectively with the President to get this done

  • Cheryl Ganley

    Why don’t we enact legislation to have similar drug pricing structures as other countries?

  • rosemariejackowski

    Yes… we need price controls on drugs and caps on hospital CEO salaries. Then we need to get rid of the insurance companies.
    Single Payer is the only answer.

  • Ned Pike

    Ah, yes. I see the Econ 101 dropouts are already here. Bernie believes that R&D costs should never factor into the price of medication; only the cost of production. He believes that shareholders in these companies should bear all of the costs of R&D.

    If shareholders can’t make a return on their R&D costs, how willing will they be to keep investing? Given that a successful drug with no issues takes at least $1 billion to move through the testing and approval processes (and complexity increases those costs exponentially), drug companies will no longer innovate and create new, potentially helpful, drugs. Bernie’s solution condemns the world to cheap generic drugs as of the implementation date of his legislation with no future development of ANYTHING.

    The disparity between world drug prices and US drug prices is exactly what Bernie advocates. Europe will only buy the drugs for the cost of production, meaning the cost of R&D is borne totally by US consumers. The fix isn’t re-importation, it’s the drug companies refusing to sell until a single global price that covers all costs and allows for reasonable profits comes into play.

    The less said about the “non-existent” fiscal calamities of Euro social medicine (c.f. the Liverpool Care Pathway), the less the single-payers’ heads explode.

    • robert bristow-johnson

      What do you mean by “reasonable profits”, Ned? We Econ 101 dropouts know about the NIH:

      NIH-funded basic research fuels the entry of new drugs into the market and provides a positive return to public investment of 43%, by some estimates.

      Andrew A. Toole (2007). “Does Public Scientific Research Complement Private Investment in Research and Development in the Pharmaceutical Industry?” Journal of Law and Economics, vol. 50
      Andrew A. Toole (2012). The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry. Research Policy, 41, pp. 1-12

      Don’t think for a minute that the Big Pharma folks are taking on the bulk of the significant risk to themselves. We are bearing the risk. We also know about the meaning of privatized profits coupled with socialized risk. So much for “free enterprise” ideals. We already have a form of socialized medicine, it’s just that we regular folks do not benefit from it.